Candriam S.C.A. 4 D Molecular Therapeutics, Inc. Transaction History
Candriam S.C.A.
- $15.4 Billion
- Q1 2024
A detailed history of Candriam S.C.A. transactions in 4 D Molecular Therapeutics, Inc. stock. As of the latest transaction made, Candriam S.C.A. holds 269,000 shares of FDMT stock, worth $5.61 Million. This represents 0.06% of its overall portfolio holdings.
Number of Shares
269,000
Previous 198,000
35.86%
Holding current value
$5.61 Million
Previous $4.01 Million
113.66%
% of portfolio
0.06%
Previous 0.03%
Shares
4 transactions
Others Institutions Holding FDMT
# of Institutions
157Shares Held
50.3MCall Options Held
718KPut Options Held
370K-
Vr Adviser, LLC New York, NY4.4MShares$91.7 Million12.03% of portfolio
-
Black Rock Inc. New York, NY4.28MShares$89.3 Million0.0% of portfolio
-
Bvf Inc San Francisco, CA3.92MShares$81.8 Million3.74% of portfolio
-
Janus Henderson Group PLC London, X03.2MShares$66.7 Million0.06% of portfolio
-
Goldman Sachs Group Inc New York, NY3.06MShares$63.8 Million0.02% of portfolio
About 4D Molecular Therapeutics, Inc.
- Ticker FDMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 32,382,400
- Market Cap $675M
- Description
- 4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical tr...